Correction to: Recurrent hospitalization among patients with atrial fibrillation undergoing Intracoronary stenting treated with 2 treatment strategies of Rivaroxaban or a dose-Adjusted oral Vitamin K antagonist treatment strategy (Circulation (2017) 135 (323-333) DOI: 10.1161/CIRCULATIONAHA.116.025783);Recurrent hospitalization among patients with atrial fibrillation undergoing intracoronary stenting treated with 2 treatment strategies of rivaroxaban or a dose-adjusted oral Vitamin K antagonist treatment strategy

Circulation

Volumn 135, Issue 4, 2017, Pages 323-333

  Gibson, C Michael ^a   Pinto, Duane S ^a   Chi, Gerald ^a   Arbetter, Douglas ^a   Yee, Megan ^a   Mehran, Roxana ^b   Bode, Christoph ^c   Halperin, Jonathan ^b   Verheugt, Freek W A ^d   Wildgoose, Peter ^e   Burton, Paul ^e   Van Eickels, Martin ^f   Korjian, Serge ^a   Daaboul, Yazan ^a   Jain, Purva ^a   Lip, Gregory Y H ^g   Cohen, Marc ^h   Peterson, Eric D ⁱ   Fox, Keith A A ^j  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

^d ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^e JANSSEN RESEARCH FOUNDATION   (Belgium)

^f BAYER PHARMA AG   (Germany)

^g UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^h NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

ⁱ DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^j UNIVERSITY OF EDINBURGH   (United Kingdom)

more..

Author keywords

atrial fibrillation; percutaneous coronary intervention; rivaroxaban; Vitamin K

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; CLOPIDOGREL; PRASUGREL; RIVAROXABAN; TICAGRELOR; BLOOD CLOTTING FACTOR 10A INHIBITOR; VITAMIN K GROUP;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BARE METAL STENT; BLEEDING; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHADS2 SCORE; CONTROLLED STUDY; CORONARY STENTING; CREATININE CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELUTING CORONARY STENT; DUAL ANTIPLATELET THERAPY; FEMALE; FOLLOW UP; HOSPITAL PATIENT; HOSPITAL READMISSION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MODERATE RENAL IMPAIRMENT; MONOTHERAPY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURGICAL MORTALITY; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; HOSPITALIZATION; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; STENT; TREATMENT OUTCOME; UTILIZATION;

AGED; ATRIAL FIBRILLATION; FACTOR XA INHIBITORS; FEMALE; HOSPITALIZATION; HUMANS; MALE; RIVAROXABAN; STENTS; TREATMENT OUTCOME; VITAMIN K;

EID: 84996615365     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIR.0000000000000495     Document Type: Erratum

References (17)

1. Rubboli A, Colletta M, Herzfeld J, Sangiorgio P, Di Pasquale G, Periprocedural and medium-Term antithrombotic strategies in patients with an indication for long-Term anticoagulation undergoing coronary angiography and intervention. Coron Artery Dis 2007 18 193 199. doi: 10.1097/MCA.0b013e328012a964
2. Wang TY, Robinson LA, Ou F-S, Roe MT, Ohman EM, Gibler WB, Smith SC, Peterson ED, Becker RC, Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. Am Heart J 2008 155 361 368
3. Pérez-Gómez F, Alegría E, Berjón J, Iriarte JA, Zumalde J, Salvador A, Mataix L, NASPEAF Investigators Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 2004 44 1557 1566. doi: 10.1016/j.jacc.2004.05.084
4. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE, A clinical trial comparing three antithrombotic-drug regimens after coronary-Artery stenting: Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998 339 1665 1671. doi: 10.1056/NEJM199812033392303
5. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S, Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006 367 1903 1912
6. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH, Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010 12 1360 1420
7. Paikin JS, Wright DS, Crowther MA, Mehta SR, Eikelboom JW, Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation 2010 121 2067 2070. doi: 10.1161/CIRCULATIONAHA.109.924944
8. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt F, Wildgoose P, Van Eickels M, Lip GY, Cohen M, Husted S, Peterson E, Fox K, An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-Adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J 2015 169 472 478.e5. doi: 10.1016/j.ahj.2014.12.006
9. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt F, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Szlosek D, Lip GY, Cohen M, Husted S, Peterson E, Fox K, An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-Adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention: PIONEER AF-PCI. N Engl J Med 2016. doi: 10.1056/NEJMoa1611594. In press
10. Wei LJ, Lin D.Y., Weissfeld L, Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc 1989 84 1065 1073
11. Popma CJ, Sheng S, Korjian S, Daaboul Y, Chi G, Tricoci P, Huang Z, Moliterno DJ, White HD, Van de Werf F, Harrington RA, Wallentin L, Held C, Armstrong PW, Aylward PE, Strony J, Mahaffey KW, Gibson CM, Lack of concordance between local investigators, angiographic core laboratory, and clinical event committee in the assessment of stent thrombosis: results from the TRACER Angiographic Substudy. Circ Cardiovasc Interv 2016 9 e003114. doi: 10.1161/CIRCINTERVENTIONS.115.003114
12. Allen LA, Spertus JA, End points for comparative effectiveness research in heart failure. Heart Fail Clin 2013 9 15 28. doi: 10.1016/j.hfc.2012.09.002
13. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ, ATHENA Investigators Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009 360 668 678. doi: 10.1056/NEJMoa0803778
14. Torp-Pedersen C, Crijns HJ, Gaudin C, Page RL, Connolly SJ, Hohnloser SH, ATHENA Investigators Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study. Europace 2011 13 1118 1126
15. Kim MM, Metlay J, Cohen A, Feldman H, Hennessy S, Kimmel S, Strom B, Doshi JA, Hospitalization costs associated with warfarin-related bleeding events among older community-dwelling adults. Pharmacoepidemiol Drug Saf 2010 19 731 736. doi: 10.1002/pds.1953
16. Ghate SR, Biskupiak J, Ye X, Kwong WJ, Brixner DI, All-cause and bleeding-related health care costs in warfarin-Treated patients with atrial fibrillation. J Manag Care Pharm 2011 17 672 684. doi: 10.18553/jmcp.2011.17.9.672
17. Björholt I, Andersson S, Nilsson GH, Krakau I, The cost of monitoring warfarin in patients with chronic atrial fibrillation in primary care in Sweden. BMC Fam Pract 2007 8 6. doi: 10.1186/1471-2296-8-6